Cogent Biosciences, Inc.
COGT
$12.23
$0.443.73%
NASDAQ
06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
---|---|---|---|---|---|
Revenue | -- | -- | -- | -- | -- |
Total Other Revenue | -- | -- | -- | -- | -- |
Total Revenue | -- | -- | -- | -- | -- |
Cost of Revenue | -- | -- | -- | -- | -- |
Gross Profit | -- | -- | -- | -- | -- |
SG&A Expenses | 32.56% | 22.73% | 22.93% | 24.83% | 22.88% |
Depreciation & Amortization | -- | -- | -- | -- | -- |
Other Operating Expenses | -- | -- | -- | -- | -- |
Total Operating Expenses | 17.39% | 20.08% | 26.63% | 26.58% | 36.75% |
Operating Income | -17.39% | -20.08% | -26.63% | -26.58% | -36.75% |
Income Before Tax | -24.73% | -23.37% | -24.95% | -27.54% | -33.75% |
Income Tax Expenses | -- | -- | -- | -- | -- |
Earnings from Continuing Operations | -24.73% | -23.37% | -24.95% | -27.54% | -33.75% |
Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
Minority Interest in Earnings | -- | -- | -- | -- | -- |
Net Income | -24.73% | -23.37% | -24.95% | -27.54% | -33.75% |
EBIT | -17.39% | -20.08% | -26.63% | -26.58% | -36.75% |
EBITDA | -17.48% | -20.21% | -26.86% | -26.77% | -37.10% |
EPS Basic | -8.06% | 99.91% | 2.76% | 0.23% | -0.75% |
Normalized Basic EPS | -8.05% | 99.91% | 8.48% | 0.25% | -0.76% |
EPS Diluted | -8.06% | 99.91% | 2.76% | 0.23% | -0.75% |
Normalized Diluted EPS | -8.05% | 99.91% | 8.48% | 0.25% | -0.76% |
Average Basic Shares Outstanding | 15.42% | 139,706.04% | 28.50% | 27.85% | 32.76% |
Average Diluted Shares Outstanding | 15.42% | 139,706.04% | 28.50% | 27.85% | 32.76% |
Dividend Per Share | -- | -- | -- | -- | -- |
Payout Ratio | -- | -- | -- | -- | -- |